PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer

(2021) Michal M Hoppe et al.   EMBO Molecular Medicine

The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences

(2021) Yasset Perez-Riverol et al.   NUCLEIC ACIDS RESEARCH

Mitochondrial biogenesis: An update

(2020) Lucia‐Doina Popov   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

(2019) Hideaki Ogiwara et al.   CANCER CELL

HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.

(2019) Takeshi Fukumoto et al.   CANCER RESEARCH

PLK1 inhibition in cancer therapy: potentials and challenges

(2019) Inas Elsayed et al.   Future Medicinal Chemistry

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response

(2019) David Sharon et al.   Science Translational Medicine

The SWI/SNF complex subunit genes: Their functions, variations, and links to risk and survival outcomes in human cancers

(2018) Sevtap Savas et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

(2018) Yonathan Lissanu Deribe et al.   NATURE MEDICINE

The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II

(2018) Marco Trizzino et al.   Cell Reports

Aurora-PLK1 cascades as key signaling modules in the regulation of mitosis

(2018) Vladimir Joukov et al.   Science Signaling

Aurora kinase A localises to mitochondria to control organelle dynamics and energy production

(2018) Giulia Bertolin et al.   eLife

PLK1, A Potential Target for Cancer Therapy

(2017) Zhixian Liu et al.   Translational Oncology

Mammalian SWI/SNF Enzymes and the Epigenetics of Tumor Cell Metabolic Reprogramming

(2017) Jeffrey A. Nickerson et al.   Frontiers in Oncology

Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

(2016) Rosie Elizabeth Ann Gutteridge et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib

(2016) Rowan E. Miller et al.   MOLECULAR CANCER THERAPEUTICS

Protein-retention expansion microscopy of cells and tissues labeled using standard fluorescent proteins and antibodies

(2016) Paul W Tillberg et al.   NATURE BIOTECHNOLOGY

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

(2016) John G Doench et al.   NATURE BIOTECHNOLOGY

Quality control of mitochondrial protein synthesis is required for membrane integrity and cell fitness

(2015) Uwe Richter et al.   JOURNAL OF CELL BIOLOGY

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

(2015) Xiaoqi Liu   Translational Oncology

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

(2015) J. Shen et al.   Cancer Discovery

Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics

(2015) C. Kadoch et al.   Science Advances

Vulnerabilities of Mutant SWI/SNF Complexes in Cancer

(2014) Katherine C. Helming et al.   CANCER CELL

Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State

(2014) Z. Li et al.   MOLECULAR AND CELLULAR BIOLOGY

Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma

(2013) Tsui-Lien Mao et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

(2013) Hyungshin Yim   ANTI-CANCER DRUGS

BAF complexes facilitate decatenation of DNA by topoisomerase IIα

(2013) Emily C. Dykhuizen et al.   NATURE

Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy

(2013) Cigall Kadoch et al.   NATURE GENETICS

Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

(2013) Richard Gorlick et al.   PEDIATRIC BLOOD & CANCER

Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters

(2013) M. Y. Tolstorukov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma

(2012) Ayse Ayhan et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Switching Polo-like kinase-1 on and off in time and space

(2012) Wytse Bruinsma et al.   TRENDS IN BIOCHEMICAL SCIENCES

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

(2012) Jennifer N. Wu et al.   Cancer Discovery

Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia

(2011) Marko Škrtić et al.   CANCER CELL

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations

(2011) Sohei Yamamoto et al.   MODERN PATHOLOGY

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

(2011) Kai Wang et al.   NATURE GENETICS

Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission

(2011) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

(2010) Siân Jones et al.   SCIENCE

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Polo-like kinases mediate cell survival in mitochondrial dysfunction

(2009) T. Matsumoto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA